AbbVie's Bretisilocin Hit With Enveric IP Claim
Enveric Biosciences is challenging AbbVie over its psychedelic candidate bretisilocin, claiming it infringes on their patent (US Patent No. 12,138,276). AbbVie is in the process of acquiring bretisilocin from Gilgamesh for up to $1.2 billion. Enveric's CEO stated they will vigorously defend their IP, and shares rose 20% as investors reacted. The outcome of the patent dispute will impact potential royalties and timelines for the Gilgamesh deal, affecting the development of a new depression therapy.
Enveric Biosciences is gearing up to challenge AbbVie over bretisilocin, saying the Phase 2 psychedelic candidate steps on its patent as AbbVie moves to buy it from Gilgamesh for up to $1.2 billion.
At issue is US Patent No. 12,138,276 on halogenated psilocybin derivatives and methods of use. Gilgamesh has already asked for a post grant review of that patent. Enveric hired Fish & Richardson and, in CEO Joseph Tucker's words, will vigorously defend its IP. Shares jumped 20% Wednesday morning as investors priced in the possibility of leverage.
Here is the rub for AbbVie. If Enveric's claim sticks, bretisilocin could face royalties, design work, or delays that complicate timelines tied to the Gilgamesh deal. If the patent is pared back or tossed, the overhang eases and development can keep pace.
Patent clarity will decide who gets paid and how fast a novel depression therapy can reach patients, with real dollars tied to exclusivity and time to market.Enveric is drawing a bright line around its patent. Watch first filings, the post grant review track, and any response from AbbVie and Gilgamesh.
